vs
Side-by-side financial comparison of EyePoint, Inc. (EYPT) and HARVARD BIOSCIENCE INC (HBIO). Click either name above to swap in a different company.
HARVARD BIOSCIENCE INC is the larger business by last-quarter revenue ($23.7M vs $619.0K, roughly 38.3× EyePoint, Inc.). HARVARD BIOSCIENCE INC runs the higher net margin — -12.0% vs -10922.3%, a 10910.3% gap on every dollar of revenue. On growth, HARVARD BIOSCIENCE INC posted the faster year-over-year revenue change (-3.3% vs -94.7%). HARVARD BIOSCIENCE INC produced more free cash flow last quarter ($-545.0K vs $-66.0M). Over the past eight quarters, HARVARD BIOSCIENCE INC's revenue compounded faster (-1.6% CAGR vs -77.0%).
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
EYPT vs HBIO — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $619.0K | $23.7M |
| Net Profit | $-67.6M | $-2.8M |
| Gross Margin | — | 59.7% |
| Operating Margin | -11364.3% | 7.2% |
| Net Margin | -10922.3% | -12.0% |
| Revenue YoY | -94.7% | -3.3% |
| Net Profit YoY | -63.3% | -15916.7% |
| EPS (diluted) | $-0.82 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $619.0K | $23.7M | ||
| Q3 25 | $966.0K | $20.6M | ||
| Q2 25 | $5.3M | $20.4M | ||
| Q1 25 | $24.5M | $21.8M | ||
| Q4 24 | $11.6M | $24.6M | ||
| Q3 24 | $10.5M | $22.0M | ||
| Q2 24 | $9.5M | $23.1M | ||
| Q1 24 | $11.7M | $24.5M |
| Q4 25 | $-67.6M | $-2.8M | ||
| Q3 25 | $-59.7M | $-1.2M | ||
| Q2 25 | $-59.4M | $-2.3M | ||
| Q1 25 | $-45.2M | $-50.3M | ||
| Q4 24 | $-41.4M | $18.0K | ||
| Q3 24 | $-29.4M | $-4.8M | ||
| Q2 24 | $-30.8M | $-2.9M | ||
| Q1 24 | $-29.3M | $-4.7M |
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 58.4% | ||
| Q2 25 | — | 56.4% | ||
| Q1 25 | — | 56.0% | ||
| Q4 24 | — | 57.1% | ||
| Q3 24 | 93.0% | 58.1% | ||
| Q2 24 | 85.2% | 57.2% | ||
| Q1 24 | 93.5% | 60.3% |
| Q4 25 | -11364.3% | 7.2% | ||
| Q3 25 | -6420.8% | 1.0% | ||
| Q2 25 | -1166.8% | -4.0% | ||
| Q1 25 | -199.7% | -228.1% | ||
| Q4 24 | -390.4% | 0.0% | ||
| Q3 24 | -311.2% | -8.5% | ||
| Q2 24 | -364.5% | -9.0% | ||
| Q1 24 | -285.2% | -9.3% |
| Q4 25 | -10922.3% | -12.0% | ||
| Q3 25 | -6183.4% | -6.0% | ||
| Q2 25 | -1114.3% | -11.2% | ||
| Q1 25 | -184.8% | -231.2% | ||
| Q4 24 | -357.3% | 0.1% | ||
| Q3 24 | -279.0% | -21.9% | ||
| Q2 24 | -325.3% | -12.7% | ||
| Q1 24 | -250.6% | -19.1% |
| Q4 25 | $-0.82 | $-0.06 | ||
| Q3 25 | $-0.85 | $-0.03 | ||
| Q2 25 | $-0.85 | $-0.05 | ||
| Q1 25 | $-0.65 | $-1.14 | ||
| Q4 24 | $-0.65 | $0.01 | ||
| Q3 24 | $-0.54 | $-0.11 | ||
| Q2 24 | $-0.58 | $-0.07 | ||
| Q1 24 | $-0.55 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $306.1M | $8.6M |
| Total DebtLower is stronger | — | $35.9M |
| Stockholders' EquityBook value | $306.1M | $13.7M |
| Total Assets | $364.0M | $80.1M |
| Debt / EquityLower = less leverage | — | 2.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $306.1M | $8.6M | ||
| Q3 25 | $204.0M | $6.8M | ||
| Q2 25 | $255.7M | $7.4M | ||
| Q1 25 | $318.2M | $5.5M | ||
| Q4 24 | $370.9M | $4.1M | ||
| Q3 24 | $253.8M | $4.6M | ||
| Q2 24 | $280.2M | $4.0M | ||
| Q1 24 | $299.3M | $4.3M |
| Q4 25 | — | $35.9M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $34.9M | ||
| Q1 25 | — | $36.4M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | — | $34.9M | ||
| Q2 24 | — | $35.7M | ||
| Q1 24 | — | $35.6M |
| Q4 25 | $306.1M | $13.7M | ||
| Q3 25 | $200.2M | $14.1M | ||
| Q2 25 | $246.0M | $15.7M | ||
| Q1 25 | $298.4M | $14.8M | ||
| Q4 24 | $336.5M | $63.3M | ||
| Q3 24 | $218.7M | $65.3M | ||
| Q2 24 | $228.3M | $67.2M | ||
| Q1 24 | $249.9M | $68.8M |
| Q4 25 | $364.0M | $80.1M | ||
| Q3 25 | $251.7M | $78.0M | ||
| Q2 25 | $301.1M | $80.1M | ||
| Q1 25 | $362.6M | $79.8M | ||
| Q4 24 | $418.5M | $126.6M | ||
| Q3 24 | $300.9M | $131.2M | ||
| Q2 24 | $324.2M | $128.9M | ||
| Q1 24 | $329.2M | $133.2M |
| Q4 25 | — | 2.61× | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | 2.45× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.52× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-65.0M | $-96.0K |
| Free Cash FlowOCF − Capex | $-66.0M | $-545.0K |
| FCF MarginFCF / Revenue | -10667.7% | -2.3% |
| Capex IntensityCapex / Revenue | 159.3% | 1.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-243.4M | $5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-65.0M | $-96.0K | ||
| Q3 25 | $-59.4M | $1.1M | ||
| Q2 25 | $-62.6M | $2.8M | ||
| Q1 25 | $-53.1M | $3.0M | ||
| Q4 24 | $-35.8M | $1.7M | ||
| Q3 24 | $-39.0M | $-842.0K | ||
| Q2 24 | $-20.2M | $-846.0K | ||
| Q1 24 | $-31.2M | $1.4M |
| Q4 25 | $-66.0M | $-545.0K | ||
| Q3 25 | $-60.2M | $877.0K | ||
| Q2 25 | $-63.8M | $2.7M | ||
| Q1 25 | $-53.4M | $2.5M | ||
| Q4 24 | $-36.2M | $1.4M | ||
| Q3 24 | $-40.6M | $-1.7M | ||
| Q2 24 | $-21.1M | $-1.7M | ||
| Q1 24 | $-32.4M | $758.0K |
| Q4 25 | -10667.7% | -2.3% | ||
| Q3 25 | -6226.9% | 4.3% | ||
| Q2 25 | -1196.5% | 13.0% | ||
| Q1 25 | -218.4% | 11.4% | ||
| Q4 24 | -312.7% | 5.8% | ||
| Q3 24 | -385.8% | -7.8% | ||
| Q2 24 | -222.4% | -7.2% | ||
| Q1 24 | -277.0% | 3.1% |
| Q4 25 | 159.3% | 1.9% | ||
| Q3 25 | 82.6% | 1.0% | ||
| Q2 25 | 22.9% | 0.4% | ||
| Q1 25 | 1.1% | 2.4% | ||
| Q4 24 | 3.3% | 1.2% | ||
| Q3 24 | 15.0% | 4.0% | ||
| Q2 24 | 9.5% | 3.5% | ||
| Q1 24 | 10.2% | 2.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 95.83× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EYPT
Segment breakdown not available.
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
